Mitchell Machtay

Summary

Affiliation: Thomas Jefferson University Hospital
Country: USA

Publications

  1. doi request reprint Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis
    Mitchell Machtay
    Jefferson Medical College and Kimmel Cancer Center of Thomas Jefferson University, Philadelphia, PA, USA
    J Clin Oncol 26:3582-9. 2008
  2. ncbi request reprint Radiotherapy with or without erythropoietin for anemic patients with head and neck cancer: a randomized trial of the Radiation Therapy Oncology Group (RTOG 99-03)
    Mitchell Machtay
    Thomas Jefferson University College of Medicine, Philadelphia, PA 19107, USA
    Int J Radiat Oncol Biol Phys 69:1008-17. 2007
  3. doi request reprint Phase I trial using the proteasome inhibitor bortezomib and concurrent chemoradiotherapy for head-and-neck malignancies
    Gregory J Kubicek
    Department of Radiation Oncology, Jefferson Medical College, Thomas Jefferson University, Philadelphia, PA, USA
    Int J Radiat Oncol Biol Phys 83:1192-7. 2012
  4. ncbi request reprint Pilot study of postoperative reirradiation, chemotherapy, and amifostine after surgical salvage for recurrent head-and-neck cancer
    Mitchell Machtay
    Department of Radiation Oncology, University of Pennsylvania Medical Center, Philadelphia, PA, USA
    Int J Radiat Oncol Biol Phys 59:72-7. 2004
  5. ncbi request reprint Signaling pathways in NSCLC as a predictor of outcome and response to therapy
    Anjali K Gupta
    Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA 19104, USA
    Lung 182:151-62. 2004
  6. ncbi request reprint Survival impact of planned restaging and early surgical salvage following definitive chemoradiation for locally advanced squamous cell carcinomas of the oropharynx and hypopharynx
    Sue S Yom
    Department of Radiation Oncology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA
    Am J Clin Oncol 28:385-92. 2005
  7. doi request reprint Phase I trial using patupilone (epothilone B) and concurrent radiotherapy for central nervous system malignancies
    Shannon Fogh
    Department of Radiation Oncology, Jefferson Medical College of Thomas Jefferson University, Philadelphia, PA 19107, USA
    Int J Radiat Oncol Biol Phys 77:1009-16. 2010
  8. pmc Phase i study of 'dose-dense' pemetrexed plus carboplatin/radiotherapy for locally advanced non-small cell lung carcinoma
    Xinglei Shen
    Department of Radiation Oncology, Kimmel Cancer Center, Jefferson Medical College of Thomas Jefferson University, Philadelphia, USA
    Radiat Oncol 6:17. 2011
  9. ncbi request reprint Preliminary investigation of symptom distress in the head and neck patient population: validation of a measurement instrument
    Heather A Jones
    Department of Radiation Oncology, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
    Am J Clin Oncol 29:158-62. 2006
  10. pmc A phase 1b trial of the combination of the antiangiogenic agent sunitinib and radiation therapy for patients with primary and metastatic central nervous system malignancies
    Evan J Wuthrick
    Department of Radiation Oncology, Jefferson Medical College of Thomas Jefferson University, Kimmel Cancer Center, Philadelphia, Pennsylvania 19107, USA
    Cancer 117:5548-59. 2011

Collaborators

Detail Information

Publications50

  1. doi request reprint Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis
    Mitchell Machtay
    Jefferson Medical College and Kimmel Cancer Center of Thomas Jefferson University, Philadelphia, PA, USA
    J Clin Oncol 26:3582-9. 2008
    ..This study evaluates clinical factors that are associated with and might predict severe late toxicity after CCRT...
  2. ncbi request reprint Radiotherapy with or without erythropoietin for anemic patients with head and neck cancer: a randomized trial of the Radiation Therapy Oncology Group (RTOG 99-03)
    Mitchell Machtay
    Thomas Jefferson University College of Medicine, Philadelphia, PA 19107, USA
    Int J Radiat Oncol Biol Phys 69:1008-17. 2007
    ..To determine whether the addition of recombinant human erythropoietin (Epo) could improve the outcomes of anemic patients receiving definitive radiotherapy for squamous cell carcinoma of the head and neck (SCCHN)...
  3. doi request reprint Phase I trial using the proteasome inhibitor bortezomib and concurrent chemoradiotherapy for head-and-neck malignancies
    Gregory J Kubicek
    Department of Radiation Oncology, Jefferson Medical College, Thomas Jefferson University, Philadelphia, PA, USA
    Int J Radiat Oncol Biol Phys 83:1192-7. 2012
    ..This Phase I dose-escalation study examined the potential of bortezomib in combination with cisplatin chemotherapy and concurrent radiation in the treatment of locally advanced and recurrent HNC...
  4. ncbi request reprint Pilot study of postoperative reirradiation, chemotherapy, and amifostine after surgical salvage for recurrent head-and-neck cancer
    Mitchell Machtay
    Department of Radiation Oncology, University of Pennsylvania Medical Center, Philadelphia, PA, USA
    Int J Radiat Oncol Biol Phys 59:72-7. 2004
    ..We designed a prospective protocol to determine the feasibility, toxicity, and preliminary efficacy of a regimen of postoperative reirradiation, chemotherapy and the radioprotector amifostine after salvage head-and-neck surgery...
  5. ncbi request reprint Signaling pathways in NSCLC as a predictor of outcome and response to therapy
    Anjali K Gupta
    Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA 19104, USA
    Lung 182:151-62. 2004
    ..This further suggests that Akt might be a useful target for sensitization of NSCLC to radiation...
  6. ncbi request reprint Survival impact of planned restaging and early surgical salvage following definitive chemoradiation for locally advanced squamous cell carcinomas of the oropharynx and hypopharynx
    Sue S Yom
    Department of Radiation Oncology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA
    Am J Clin Oncol 28:385-92. 2005
    ..The authors reviewed the practice of planned post-RT restaging to determine its impact on the success of early surgical salvage...
  7. doi request reprint Phase I trial using patupilone (epothilone B) and concurrent radiotherapy for central nervous system malignancies
    Shannon Fogh
    Department of Radiation Oncology, Jefferson Medical College of Thomas Jefferson University, Philadelphia, PA 19107, USA
    Int J Radiat Oncol Biol Phys 77:1009-16. 2010
    ....
  8. pmc Phase i study of 'dose-dense' pemetrexed plus carboplatin/radiotherapy for locally advanced non-small cell lung carcinoma
    Xinglei Shen
    Department of Radiation Oncology, Kimmel Cancer Center, Jefferson Medical College of Thomas Jefferson University, Philadelphia, USA
    Radiat Oncol 6:17. 2011
    ..This phase I study investigates the feasibility of carboplatin plus dose-dense (q2-week) pemetrexed given concurrently with radiotherapy (XRT) for locally advanced and oligometastatic non-small cell lung cancer (NSCLC)...
  9. ncbi request reprint Preliminary investigation of symptom distress in the head and neck patient population: validation of a measurement instrument
    Heather A Jones
    Department of Radiation Oncology, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
    Am J Clin Oncol 29:158-62. 2006
    ..Thus, the specific aim of this pilot study was to estimate the reliability and validity of a modified version of a symptom distress scale used to assess the qualitative difference in symptom distress between the 2 populations...
  10. pmc A phase 1b trial of the combination of the antiangiogenic agent sunitinib and radiation therapy for patients with primary and metastatic central nervous system malignancies
    Evan J Wuthrick
    Department of Radiation Oncology, Jefferson Medical College of Thomas Jefferson University, Kimmel Cancer Center, Philadelphia, Pennsylvania 19107, USA
    Cancer 117:5548-59. 2011
    ..In this phase 1 trial, the authors evaluated sunitinib combined with radiation therapy (RT) for the treatment of primary or metastatic central nervous system (CNS) malignancies...
  11. pmc FDG-PET staging and importance of lymph node SUV in head and neck cancer
    Gregory J Kubicek
    Thomas Jefferson University Hospital, Philadelphia, PA, USA
    Head Neck Oncol 2:19. 2010
    ..The NCCN guidelines do not recommend FDG-PET as a part of standard workup. The purpose of this report is to examine the role of FDG-PET imaging in altering management and providing prognostic information for HNC...
  12. ncbi request reprint Final report of a pilot trial of accelerated radiotherapy plus concurrent 96-hour infusional paclitaxel for locally advanced head and neck cancer
    Mary K Bucci
    Department of Radiation Oncology, University of Pennsylvania Medical Center, Philadelphia, Pennsylvania, USA
    Am J Clin Oncol 27:595-602. 2004
    ..LRC and survival compare favorably with other aggressive regimens for this poor-prognosis population. Further study of accelerated XRT with concurrent chemotherapy is indicated...
  13. ncbi request reprint Pilot study of accelerated radiotherapy with concurrent chemotherapy for stage III non-small cell lung cancer
    Mitchell Machtay
    Department of Radiation Oncology, Jefferson Medical College, Thomas Jefferson University, 111 South 11th Street, Philadelphia, PA 19104, USA
    Semin Oncol 32:S9-12. 2005
    ..Extreme caution must be exercised in designing studies of XRT dose intensification with concurrent chemotherapy...
  14. pmc Fractionated stereotactic radiation therapy improves cranial neuropathies in patients with skull base meningiomas: a retrospective cohort study
    Xinglei Shen
    Department of Radiation Oncology, Kimmel Cancer Center, Jefferson Medical College of Thomas Jefferson University, Philadelphia, PA, USA
    Radiat Oncol 7:225. 2012
    ..We review the experience at Thomas Jefferson University using FSRT in the management of these patients with a focus on symptom outcomes...
  15. ncbi request reprint A Phase II trial of subcutaneous amifostine and radiation therapy in patients with head-and-neck cancer
    Pramila Rani Anne
    Thomas Jefferson University Hospital, Bodine Center for Cancer Research, Philadelphia, PA 19107, USA
    Int J Radiat Oncol Biol Phys 67:445-52. 2007
    ..Intravenous amifostine 200 mg/m2 reduces xerostomia in head-and-neck cancer patients. This Phase II study evaluated subcutaneous (s.c.) amifostine in a similar patient population...
  16. doi request reprint Pretreatment FDG-PET standardized uptake value as a prognostic factor for outcome in head and neck cancer
    Mitchell Machtay
    Department of Radiation Oncology, Jefferson Medical College and the Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania, USA
    Head Neck 31:195-201. 2009
    ..We studied the potential prognostic significance of pretreatment 18-fluorodeoxyglucose-positron emission tomography (FDG-PET) standardized uptake value (SUV) in squamous cell carcinoma of the head and neck (SCCHN)...
  17. ncbi request reprint Relative risk of stroke in head and neck carcinoma patients treated with external cervical irradiation
    Jeffrey C Haynes
    Department of Radiation Oncology, University of Pennsylvania Medical Center, Philadelphia, Pennsylvania 19104, USA
    Laryngoscope 112:1883-7. 2002
    ..To determine the rate of cerebrovascular events (stroke) in patients irradiated to high doses for squamous cell carcinoma of the head and neck...
  18. ncbi request reprint Two commonly used neoadjuvant chemoradiotherapy regimens for locally advanced stage III non-small cell lung carcinoma: long-term results and associations with pathologic response
    Mitchell Machtay
    Department of Radiation Oncology, University of Pennsylvania Medical Center, Philadelphia, PA 19104, USA
    J Thorac Cardiovasc Surg 127:108-13. 2004
    ....
  19. doi request reprint New advances in high-technology radiotherapy for head and neck cancer
    Gregory J Kubicek
    Department of Radiation Oncology, Jefferson Medical College, Thomas Jefferson University, Philadelphia, PA 19107, USA
    Hematol Oncol Clin North Am 22:1165-80, viii. 2008
    ..Some of these advances are discussed in this article...
  20. doi request reprint Daily image guidance with cone-beam computed tomography for head-and-neck cancer intensity-modulated radiotherapy: a prospective study
    Robert B Den
    Department of Radiation Oncology, Thomas Jefferson University Hospital, Philadelphia, PA 19107 5097, USA
    Int J Radiat Oncol Biol Phys 76:1353-9. 2010
    ....
  21. ncbi request reprint Neck dissection followed by chemoradiotherapy for stage IV (N+) oropharynx cancer
    Andrew Cupino
    Department of Radiation Oncology, Jefferson Medical College, Thomas Jefferson University, Philadelphia, PA, USA
    Otolaryngol Head Neck Surg 137:416-21. 2007
    ..This study evaluated the strategy of performing neck dissection (ND) without primary tumor resection prior to definitive chemoradiotherapy (CRT) for N2+ oropharynx cancer...
  22. ncbi request reprint Gustatory impairment in patients undergoing head and neck irradiation
    Natasha Mirza
    Department of Otolaryngology, Head and Neck Surgery, University of Pennsylvania, 3400 Spruce Street, Philadelphia, PA 19104, USA
    Laryngoscope 118:24-31. 2008
    ..To determine whether radiation alters taste function and structure...
  23. pmc Phase I trial using proteasome inhibitor bortezomib and concurrent temozolomide and radiotherapy for central nervous system malignancies
    Gregory J Kubicek
    Department of Radiation Oncology, Jefferson Medical College of Thomas Jefferson University, Philadelphia, PA, USA
    Int J Radiat Oncol Biol Phys 74:433-9. 2009
    ..To evaluate the toxicity and response rate of bortezomib with concurrent radiotherapy and temozolomide in the treatment of patients with central nervous system malignancies...
  24. ncbi request reprint Report on a randomized trial comparing two forms of immobilization of the head for fractionated stereotactic radiotherapy
    Greg Bednarz
    Department of Radiation Oncology, Kimmel Cancer Center, Jefferson Medical College, Philadelphia, Pennsylvania 19107, USA
    Med Phys 36:12-7. 2009
    ..00+1.04 mm for frame. Both immobilization techniques were highly effective, but the GTC frame was more accurate. To optimize the accuracy of SRT, daily kilovolt image guidance is recommended with either immobilization system...
  25. doi request reprint Radiation treatment breaks and ulcerative mucositis in head and neck cancer
    Gregory Russo
    Department of Radiation Oncology, Jefferson Medical College, Philadelphia, Pennsylvania 19107 5097, USA
    Oncologist 13:886-98. 2008
    ..Continued investigation is needed to identify superior radiation treatment regimens, technology, and supportive care that reduce unplanned radiation treatment breaks with the goal of improving clinical outcomes in head and neck cancer...
  26. ncbi request reprint Effect of overall treatment time on outcomes after concurrent chemoradiation for locally advanced non-small-cell lung carcinoma: analysis of the Radiation Therapy Oncology Group (RTOG) experience
    Mitchell Machtay
    Department of Radiation Oncology, Thomas Jefferson University, Philadelphia, PA, USA
    Int J Radiat Oncol Biol Phys 63:667-71. 2005
    ..To determine whether overall treatment time affects outcomes after definitive concurrent chemoradiotherapy for locally advanced non-small-cell lung carcinoma (NSCLC)...
  27. pmc The addition of amifostine to carboplatin and paclitaxel based chemoradiation in locally advanced non-small cell lung cancer: Long-term follow-up of Radiation Therapy Oncology Group (RTOG) randomized trial 9801
    Yaacov Richard Lawrence
    Sheba Medical Center, Tel Hashomer, Israel Thomas Jefferson University Hospital, Philadelphia, PA, United States Electronic address
    Lung Cancer 80:298-305. 2013
    ..We report the long-term results of RTOG 9801, a randomized trial investigating the ability of amifostine, a radioprotector, to reduce chemoradiation-induced esophagitis...
  28. ncbi request reprint Importance of the treatment package time in surgery and postoperative radiation therapy for squamous carcinoma of the head and neck
    David I Rosenthal
    Department of Radiation Oncology, Hospital of the University of Pennsylvania, 3400 Spruce Street, 2 Donner, Philadelphia, PA 19104, USA
    Head Neck 24:115-26. 2002
    ..Patients were also divided into intermediate- and high-risk groups on the basis of eligibility for RTOG 95-01. Univariate (logrank) and multivariate analyses were performed...
  29. pmc Systemic polyethylene glycol-modified (PEGylated) superoxide dismutase and catalase mixture attenuates radiation pulmonary fibrosis in the C57/bl6 mouse
    Mitchell Machtay
    Department of Medicine, Pulmonary, Allergy, and Critical Care Division, Thomas Jefferson University Medical Center, Philadelphia, PA 19104, USA
    Radiother Oncol 81:196-205. 2006
    ..Since oxidative injury is implicated in radiation-induced tissue damage to the lung, we studied systemically administered polyethylene glycol (PEGylated) antioxidant enzymes (AOEs) as pulmonary radioprotectors in mice...
  30. ncbi request reprint Local recurrence in head and neck cancer: relationship to radiation resistance and signal transduction
    Anjali K Gupta
    Department of Radiation Oncology, University of Pennsylvania, Philadelphia, Pennsylvania 19104 6072, USA
    Clin Cancer Res 8:885-92. 2002
    ..We have shown previously that radioresistance could be conferred via the Ras-PI3K pathway. Here we investigate the contribution of EGFR to this pathway and its impact on treatment outcome...
  31. ncbi request reprint Complex and controversial issues in locally advanced non-small cell lung carcinoma
    Mitchell Machtay
    University of Pennsylvania Medical Center, Philadelphia, Pennsylvania 19104, USA
    Semin Surg Oncol 21:128-37. 2003
    ..This article summarizes the advances in the treatment of locally advanced NSCLC over the past several decades and explores some of the many remaining controversies and areas for future investigation...
  32. ncbi request reprint Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck
    Jay S Cooper
    New York University Medical Center, New York, USA
    N Engl J Med 350:1937-44. 2004
    ..We tested the hypothesis that concurrent postoperative administration of cisplatin and radiotherapy would improve the rate of local and regional control...
  33. ncbi request reprint Final report of RTOG 9610, a multi-institutional trial of reirradiation and chemotherapy for unresectable recurrent squamous cell carcinoma of the head and neck
    Sharon A Spencer
    Department of Radiation Oncology, University of Alabama at Birmingham, Birmingham, Alabama, USA
    Head Neck 30:281-8. 2008
    ....
  34. ncbi request reprint Pathological response to preoperative chemoradiation worsens with anemia in non-small cell lung cancer patients
    Theodore J Robnett
    Radiation Oncology Centers, a division of Radiological Associates of Sacramento Medical Group, California, USA
    Cancer J 8:263-7. 2002
    ..We analyzed our series of patients treated with preoperative chemoradiation for stage IIIA non-small cell lung carcinoma...
  35. ncbi request reprint Organ preservation therapy using induction plus concurrent chemoradiation for advanced resectable oropharyngeal carcinoma: a University of Pennsylvania Phase II Trial
    Mitchell Machtay
    Department of Radiation Oncology, University of Pennsylvania Medical Center, Philadelphia 19104, USA
    J Clin Oncol 20:3964-71. 2002
    ..To determine the efficacy, feasibility, and toxicity of a new regimen for locally advanced oropharyngeal carcinoma...
  36. ncbi request reprint The early rad catches the tumor?
    Mitchell Machtay
    J Clin Oncol 20:3045-7. 2002
  37. ncbi request reprint A phase III comparison of radiation therapy with or without recombinant beta-interferon for poor-risk patients with locally advanced non-small-cell lung cancer (RTOG 93-04)
    Jeffrey D Bradley
    Radiation Oncology Center, Washington University Medical Center, St Louis, MO 63110, USA
    Int J Radiat Oncol Biol Phys 52:1173-9. 2002
    ..Based on these data, the Radiation Therapy Oncology Group (RTOG) initiated a Phase III trial to test the efficacy of beta-interferon in poor-risk patients with Stages IIIA and IIIB non-small-cell lung carcinoma...
  38. ncbi request reprint Combined modality therapy for non-small cell lung carcinoma
    Mitchell Machtay
    Department of Radiation Oncology, University of Pennsylvania Medical Center, Philadelphia 19104 4283, USA
    Cancer J 8:S55-67. 2002
    ..Targeted therapies appear promising, and expedited evaluation in Stage III NSCLC is warranted...
  39. ncbi request reprint A phase I study of SPI-077 (Stealth liposomal cisplatin) concurrent with radiation therapy for locally advanced head and neck cancer
    David I Rosenthal
    Department of Radiation Oncology, Head and Neck Surgery, Hospital of the University of Pennsylvania, Philadelphia 19104, USA
    Invest New Drugs 20:343-9. 2002
    ..We performed a Phase I study of Stealth liposomal cisplatin (SPI-077) concurrent with RT for head and neck squamous cell carcinoma (HNSCC)...
  40. ncbi request reprint Nasopharyngeal carcinoma treated with external radiotherapy, brachytherapy, and concurrent/adjuvant chemotherapy
    Albert S DeNittis
    Department of Radiation Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA 19104, U S A
    Am J Clin Oncol 25:93-5. 2002
    ..No patient has had a local or neck failure. Chemoradiation plus brachytherapy offers encouraging survival and local-regional control. Further study of this regimen as an alternative or adjunct to intensity-modulated EBXRT is warranted...
  41. ncbi request reprint Effect of a short course of neoadjuvant hormonal therapy on the response to subsequent androgen suppression in prostate cancer patients with relapse after radiotherapy: a secondary analysis of the randomized protocol RTOG 86-10
    William U Shipley
    Massachusetts General Hospital, Boston, MA 02114, USA
    Int J Radiat Oncol Biol Phys 54:1302-10. 2002
    ....
  42. ncbi request reprint Locally recurrent, previously irradiated head and neck cancer: concurrent re-irradiation and chemotherapy, or chemotherapy alone?
    Stuart J Wong
    Division of Neoplastic Diseases, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI 53226, USA
    J Clin Oncol 24:2653-8. 2006
    ....
  43. ncbi request reprint Altered fractionation: a fractional benefit?
    Lori Wirth
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    Lancet 368:819-21. 2006
  44. ncbi request reprint Phase II trial of postoperative adjuvant paclitaxel/carboplatin and thoracic radiotherapy in resected stage II and IIIA non-small-cell lung cancer: promising long-term results of the Radiation Therapy Oncology Group--RTOG 9705
    Jeffrey D Bradley
    Department of Radiation Oncology, Washington University Medical Center, 4921 Parkview Place LL, Mail Stop 90 38 635, St Louis, MO 63110, USA
    J Clin Oncol 23:3480-7. 2005
    ....
  45. ncbi request reprint Phase I study of Paclitaxel given by seven-week continuous infusion concurrent with radiation therapy for locally advanced non-small cell lung cancer
    David I Rosenthal
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    J Thorac Oncol 1:38-45. 2006
    ....
  46. ncbi request reprint Randomized trial of amifostine in locally advanced non-small-cell lung cancer patients receiving chemotherapy and hyperfractionated radiation: radiation therapy oncology group trial 98-01
    Benjamin Movsas
    Department of Radiation Oncology, Henry Ford Health System, 2799 W Grand Blvd, Detroit, MI 48202, USA
    J Clin Oncol 23:2145-54. 2005
    ..To test the ability of the cytoprotectant, amifostine, to reduce chemoradiotherapy-induced esophagitis and evaluate its influence on quality of life (QOL) and swallowing symptoms...
  47. ncbi request reprint Intraobserver variability in the MR determination of tumor volume in squamous cell carcinoma of the pharynx
    Andrew R Gordon
    Department of Radiology, University of Pennsylvania Medical Center, Philadelphia 19104, USA
    AJNR Am J Neuroradiol 25:1092-8. 2004
    ..We determined the intraobserver variability of MR imaging-based volume measurements of these cancers and their regional metastases...
  48. ncbi request reprint Concurrent radiochemotherapy in the treatment of locally advanced non-small cell lung cancer
    Branislav Jeremic
    Department of Radiation Oncology, Klinikum rechts der Isar, Technical University Munich, Ismaninger Strasse 22, D 81675 Munich, Germany
    Hematol Oncol Clin North Am 18:91-100. 2004
    ..Newer RT technologies, third-generation CHT drugs, and widely used radioprotectors represent the current framework for numerous clinical studies that ultimately will help optimize the treatment of this disease...
  49. ncbi request reprint Phase I's, photons, and philosophies: new tactics for exploratory clinical trials of concurrent chemoradiation
    Mitchell Machtay
    J Clin Oncol 22:214-6. 2004
  50. ncbi request reprint Study of paclitaxel, etoposide, and cisplatin chemotherapy combined with twice-daily thoracic radiotherapy for patients with limited-stage small-cell lung cancer: a Radiation Therapy Oncology Group 9609 phase II study
    David S Ettinger
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231 1000, USA
    J Clin Oncol 23:4991-8. 2005
    ....